Valerie Lau

APAC Chief Commercial Officer
Lotus Pharmaceutical Co., Ltd.

Valerie Lau is the APAC Chief Commercial Officer at Lotus Pharmaceutical, where she oversees and optimizes operations across the Asia-Pacific region. She holds a Bachelor of Business – Marketing (Hons) from Nanyang Technological University and boasts over two decades of experience in the healthcare industry.
She has served in key positions at renowned pharmaceutical companies, including Novartis, Menarini, Ascensia Diabetes Care, and Sanofi. Her extensive background spans various sectors, such as consumer healthcare, medical devices, aesthetics, and pharmaceuticals.
Her commercial operational management experience spans multiple markets in the Asia-Pacific region, including China, the Philippines, Singapore, Malaysia, Australia, Taiwan, Korea, and Hong Kong. Since joining Lotus Pharmaceutical, she has driven growth in the Asia market and led her team to achieve business acquisitions and sustainable growth. 
Lotus is Taiwan's largest publicly listed international pharmaceutical company by revenue, having achieved double-digit revenue growth for the fifth consecutive year. The company has more than 250 commercial products, including oncology, central nervous system, nephrology, and women's healthcare. Valerie leads the Lotus APAC commercial team, which is committed to identifying collaboration opportunities in line with Lotus’ mission to provide better, safer, and more affordable medicine globally.
 

Speech title & Synopsis

Outstanding Company of the Year

Founded in 1966, Lotus (1795: TT) is an international pharmaceutical company with global presence, focused on commercializing novel and generic pharmaceuticals, offering patients better, safe and more accessible medicines. The Company has a recognized best-in-class R&D and manufacturing platform in Asia and has established partnerships in nearly every global market including the U.S., Europe, Japan, China, and Brazil. Lotus runs over 100 strategically selected pharmaceutical projects in development and registrations across Asia and the US, with over 250 commercial products. The Company invests in diversified best portfolio consisting of high-barrier oncology, complex generics as well as 505(b)2 and NCE via internal R&D investment and licensing-in partnership, and also strengthens its portfolio competitiveness by adding biosimilar products with support from strategic partners. Its industry-leading infrastructure certified by most of the advanced regulatory authorities around the world, including US FDA, EU EMA, Japan PMDA, China FDA, and Brazil ANVISA.